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Summary
Objective:	Previous	studies	suggest	that	androgens	have	a	sexually	dimorphic	impact	
on	metabolic	dysfunction.	However,	the	sex‐specific	link	between	circulating	andro‐
gens	and	risk	of	type	2	diabetes	mellitus	(T2DM)	has	not	been	examined	in	a	large	
scale,	longitudinal	cohort,	a	task	we	undertook	in	this	study.
Design:	A	retrospective	cohort	study	in	a	UK	primary	care	database.
Patients:	We	included	men	and	women	with	available	serum	testosterone	and	sex	
hormone‐binding	globulin	(SHBG)	results.
Measurements:	We	 categorized	 serum	concentrations	 according	 to	 clinically	 rele‐
vant	cut‐off	points	and	calculated	crude	and	adjusted	T2DM	Incidence	Rate	Ratios	
(IRRs	and	aIRRs).
Results:	Serum	testosterone	concentrations	were	available	in	70	541	men	and	81	889	
women;	serum	SHBG	was	available	in	15	907	men	and	42	034	women.	In	comparison	
to	a	 reference	cohort	with	serum	testosterone	≥20	nmol/L,	men	with	 lower	serum	
testosterone	had	a	significantly	increased	risk	of	T2DM,	with	the	highest	risk	in	those	
with	 serum	 testosterone	 <7	nmol/L	 (aIRR	 2.71,	 95%	 CI	 2.34‐3.14,	 P	<	0.001).	 In	
women,	the	risk	of	T2DM	started	to	increase	significantly	when	serum	testosterone	
concentrations	exceeded	1.5	nmol/L,	with	the	highest	risk	in	women	with	serum	tes‐
tosterone	≥3.5	nmol/L	(aIRR	1.98,	95%	CI	1.55‐2.52,	P	<	0.001).	These	observations	
were	verified	in	a	continuous	rather	than	categorized	analysis.	The	risk	of	T2DM	in‐
creased	in	men	and	women	with	serum	SHBG	<40	and	<50	nmol/L,	respectively.
Conclusions/Interpretation:	In	this	longitudinal	study,	we	found	sexually	dimorphic	
associations	between	serum	testosterone	and	risk	of	incident	T2DM.	Androgen	defi‐
ciency	and	excess	should	be	considered	important	risk	factors	for	diabetes	in	men	
and	women,	respectively.
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1  | INTRODUC TION
Sex	differences	are	critical	in	the	epidemiology	and	pathophysiology	of	
metabolic	disease,	with	an	increased	incidence	of	type	2	diabetes	mel‐
litus	(T2DM)	and	cardiovascular	disease	in	men.1	Sex	hormones	such	
as	androgens	may	mediate	these	differences,	but	the	association	be‐
tween	androgens	and	metabolic	dysfunction	is	complex	and	sex‐spe‐
cific.2	Androgen	excess	has	recently	been	identified	as	an	independent	
risk	 factor	 for	 non‐alcoholic	 fatty	 liver	 disease	 (NAFLD)	 in	women3 
and	promotes	 lipid	accumulation	 in	 female	adipose	 tissue	as	well	 as	
systemic	 lipotoxicity.4	 Female‐to‐male	 gender	 reassignment	patients	
undergoing	 androgen	 therapy	 develop	 dyslipidemia	 and	 abnormal	
body	composition.5,6	Mirroring	this,	the	adverse	metabolic	phenotype	
of	male	androgen	deficiency	bears	a	striking	similarity	 to	 that	of	 fe‐
male	androgen	excess;	lower	testosterone	levels	in	men	are	associated	
with	 impaired	glucose	homoeostasis,	hepatic	 steatosis	and	coronary	
artery	disease.1,7,8	A	number	of	meta‐analyses	support	a	sex‐specific	
relationship	between	androgens	and	the	risk	of	metabolic	dysfunction	
and	suggest	that	low	circulating	sex	hormone‐binding	globulin	(SHBG)	
concentrations	may	be	metabolically	harmful	in	both	sexes.8,9
Delineating	an	independent	role	for	androgens	in	the	pathogen‐
esis	of	T2DM	is	confounded	by	changes	in	body	composition,	body	
mass	index	and	lean	mass	observed	in	disorders	of	androgen	excess	
and	 deficiency.10	 Against	 the	 background	 of	 a	 global	 epidemic	 of	
T2DM,11	there	is	an	urgent	health	need	to	understand	the	sexually	
dimorphic	role	played	by	androgens	in	the	pathogenesis	of	hypergly‐
caemia.	The	shared	constellation	of	risk	factors	observed	in	women	
with	androgen	excess	and	men	with	androgen	deficiency	suggests	
that	circulating	androgen	concentrations	common	to	both	disorders	
may	 be	 metabolically	 disadvantageous.2	 To	 our	 knowledge,	 how‐
ever,	 no	 large	 longitudinal	 studies	 have	 specifically	 examined	 the	
association	between	circulating	androgen	exposure	per	se	and	risk	
of	T2DM	in	a	sex‐specific	context.
The	aim	of	this	study	was	to	investigate	the	independent	sex‐spe‐
cific	association	between	serum	testosterone	concentrations	and	the	
risk	of	hyperglycaemia	 in	men	and	women	by	undertaking	a	 retro‐
spective	cohort	study	in	a	large	and	diverse	UK	population	base.
2  | MATERIAL S AND METHODS
2.1 | Database
A	large	primary	care	database	in	the	UK	with	contribution	from	over	
700	general	practices	(14	million	patients)	was	utilized	for	this	study.	
Data	 from	 practices	 that	 use	 VISION	 Electronic	 Medical	 Record	
(EMR)	 are	 gathered,	 anonymized	 and	 released	 for	 research	 pur‐
pose.12	The	resulting	database,	The	Health	 Improvement	Network	
(THIN)	database	holds	data	on	demographic	characteristics,	clinical	
diagnosis,	 physical	 measurement,	 laboratory	 results	 and	 prescrip‐
tions.	The	THIN	database	is	broadly	representative	of	the	UK	popula‐
tion	structure13	and	has	been	utilized	for	numerous	epidemiological	
studies,	including	studies	on	T2DM14,15	and	sex	hormones.3,14,15
2.2 | Testosterone and sex hormone‐binding 
globulin (SHBG) measurements
Men	or	women	over	the	age	of	16	who	had	a	measurement	of	the	
serum	 concentration	 of	 testosterone	 or	 SHBG	 between	 1st	 of	
January	2000	and	15th	of	May	2016	were	eligible	to	take	part	in	the	
study.	Common	clinical	indications	for	these	measurements	include	
suspected	polycystic	ovary	syndrome	 (PCOS)	 in	women,	 infertility	
investigations	 in	 both	 sexes	 and	 erectile	 dysfunction	 in	 men.16,17 
Where	multiple	measurements	were	available	in	one	individual,	the	
first	measurement	was	utilized.	Patients	with	the	outcome	of	inter‐
est	(T2DM)	preceding	the	index	date	were	excluded	from	the	study.
2.3 | Exposure categories
To	explore	non‐linear	relationships,	establish	gradient	increase	and	
assess	 risk	 within	 the	 normal	 range,	 measurements	 were	 catego‐
rized	 by	 applying	 clinically	 relevant	 cut‐off	 points	 for	 serum	 con‐
centrations	 (nmol/L).3	 For	 women,	 testosterone	 was	 grouped	 as	
<1.0	nmol/L	(reference	group),	1.0‐1.49,	1.5‐1.99,	2.0‐2.49,	2.5‐2.99,	
3.0‐3.49	and	>3.5	nmol/L.	For	men,	the	groups	were	as	follows:	<7,	
7‐9.9,	 10.0‐14.9,	 15‐19.9,	 >20.0	nmol/L	 (reference	 group)	 nmol/L.	
For	both	sexes,	SHBG	was	categorized	as	>60.0	nmol/L	 (reference	
group),	 50.0‐59.9,	 40.0‐49.9,	 30.0‐39.9,	 20.0‐29.9	 and	<20	nmol/L.	
Exposures	 were	 also	 treated	 as	 continuous	 variables	 and	 risk	 of	
T2DM	assessed.
2.4 | Follow‐up period
The	date	of	measurement	of	 testosterone	or	SHBG	served	as	 the	
index	date.	Each	participant	was	 followed	up	 from	 the	 index	date	
until	the	exit	date.	Exit	date	was	defined	as	the	earliest	of	the	fol‐
lowing	dates:	outcome	(diagnosis	of	T2DM),	study	end,	death	or	the	
date	they	left	the	general	practice	or	the	general	practice	stopped	
contributing	to	the	database.
2.5 | Outcome and covariates
A	clinical	diagnosis	of	T2DM	by	the	general	practitioner	was	the	
outcome	of	interest.	In	the	UK,	the	Quality	Outcome	Framework	
(QOF)	in	general	practices	ensures	high‐quality	data	on	important	
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comorbidities	 such	 as	 cardiovascular	 disease,	 hypertension	 and	
T2DM.18	Within	 the	database,	diagnostic	 codes	 for	T2DM	were	
identified	based	on	Read	codes,	 a	hierarchical	 coding	 system	 to	
record	 signs,	 symptoms,	 procedures	 and	 diagnosis	 in	 primary	
care.3	Covariates	that	are	independent	predictors	of	T2DM	other	
than	the	exposure	of	 interest	were	selected	on	the	basis	of	bio‐
logical	plausibility	and	previous	 literature.19	These	 included	age,	
body	mass	index	(BMI),	Townsend	deprivation	score	and	smoking	
status.
2.6 | Statistical analysis
Baseline	 data	 of	 each	 category	 in	 the	 serum	 testosterone	 and	
SHBG	cohorts	were	reported	separately	for	men	and	women	as	
mean	 (standard	deviation)	 or	median	 (interquartile	 range	 [IQR])	
as	 appropriate	 for	 continuous	 variables	 and	 as	 proportions	 for	
categorical	 variables.	 Crude	 Incidence	Rate	 Ratio	 (IRR)	 and	 ad‐
justed	 Incidence	 Rate	 Ratio	 (aIRR)	were	 calculated	 by	 applying	
Poisson	regression	offsetting	for	the	person‐years	of	follow‐up.	
Covariates	adjusted	 for	 in	 the	model	were	age,	BMI,	Townsend	
quintiles	 and	 smoking	 status.	 In	 women,	 an	 additional	 model	
included	 polycystic	 ovary	 syndrome	 (PCOS)	 as	 a	 covariate	 to	
explore	 if	 the	risk	of	T2DM	in	women	was	 independent	of	a	di‐
agnosis	of	PCOS.	 In	an	additional	 sensitivity	analysis,	when	ad‐
justing	 for	 PCOS.	We	 accepted	 the	 presence	 of	 hirsutism	 and	
anovulation	as	indicative	of	PCOS	given	that	the	diagnosis	is	un‐
derreported	in	primary	care.
Where	 missing	 data	 existed	 (BMI,	 Townsend	 or	 smoking),	 we	
created	a	 separate	 category	 so	 that	 all	 available	data	 is	 utilized	 in	
the	analysis.	BMI	was	categorized	as	per	WHO	recommendation	into	
<25.0,	25‐29.0	and	>30	kg/m2.	All	analyses	were	performed	in	Stata	
14.0	(StataCorp	LLC,	College	Station,	TX,	USA).
2.7 | Subgroup analysis
In	women,	we	performed	stratified	analysis	by	age	(<50	and	50	years	
and	above)	to	explore	if	the	association	was	similar	before	and	after	
the	average	age	of	menopause.	A	similar	age‐stratified	analysis	was	
also	carried	out	in	men.	In	addition	to	this,	in	those	patients	with	si‐
multaneous	measurements	of	testosterone	and	SHBG,	a	free	andro‐
gen	index	(FAI)	was	calculated	([T	×	100]/SHBG),	and	risk	of	T2DM	
calculated	to	control	for	the	confounding	effect	of	low	SHBG	levels.
2.8 | Ethical approval
This	study	used	routinely	collected,	anonymized	primary	care	data.	
Patients	were	not	involved	in	the	study,	and	therefore,	no	consent	
was	required.	Research	using	THIN	data	was	approved	by	the	NHS	
South‐East	Multicentre	 Research	 Ethics	 Committee	 in	 2003,	with	
the	condition	that	studies	undergo	independent	scientific	review.20 
Approval	for	this	analysis	was	obtained	from	the	Scientific	Review	
Committee	for	the	use	of	THIN	data	in	January	2018	(SRC	reference	
number	17THIN106).
3  | RESULTS
3.1 | Characteristics of the cohorts with serum 
testosterone and SHBG measurements
A	total	of	152	430	participants	in	the	cohort	with	available	serum	
testosterone	 measurement	 results	 (testosterone	 cohort;	 70	541	
men	and	81	889	women)	and	a	total	of	57	942	participants	(15	907	
men	and	42	035	women)	 in	 the	SHBG	cohort,	 both	derived	 from	
the	 THIN	 database,	met	 the	 inclusion	 criteria	 and	were	 included	
in	the	current	study.	Median	follow‐up	in	the	testosterone	cohort	
was	 3.3	years	 (IQR:1.5‐6.1)	 in	men	 and	3.2	 (IQR:1.3‐6.2)	 years	 in	
women.	 In	 the	 SHBG	 cohort,	median	 follow‐up	was	 2.8	 (1.3‐4.9)	
years	 in	men	 and	 2.8	 (1.2‐5.4)	 in	women.	 The	mean	 age	 for	men	
was	51.6	 (SD	14.8)	years	 in	the	testosterone	cohort	and	51.7	 (SD	
16.0)	years	in	the	SHBG	cohort.	For	women,	mean	age	was	33.2	(SD	
10.9)	years	in	the	testosterone	cohort	and	32.1	(SD	10.6)	years	in	
the	SHBG	cohort.	In	total,	40	464	(57.4%)	men	in	the	testosterone	
cohort	and	9795	(61.6%)	men	in	the	SHBG	cohort	were	overweight	
or	 obese	 (BMI	≥	25	kg/m2).	 Among	women,	 36	640	 (44.7%)	were	
obese	or	overweight	in	the	testosterone	cohort	and	19	270	(45.8%)	
in	the	SHBG	cohort.	Approximately	21%	of	men	and	22%	of	women	
were	smokers	across	both	testosterone	and	SHBG	cohorts	(Table	1).	
A	diagnosis	of	PCOS	was	only	documented	in	6.3%	(N	=	5136)	and	
7.9%	(N	=	3303)	of	the	female	testosterone	and	SHBG	cohorts,	re‐
spectively.	However,	clinical	features	suggestive	of	PCOS,	anovula‐
tion	and	clinical	evidence	of	hirsutism,	were	documented	in	25.8%	
and	11.2%	of	the	female	testosterone	cohort,	respectively,	and	in	
26.9%	and	12.1%	of	the	female	SHBG	cohort,	respectively.
Biochemical	 evidence	 of	 male	 androgen	 deficiency	 (serum	
	testosterone	<	7	nmol/L)	was	observed	in	5862	men	(8.3%).	Biochemical	
evidence	of	 female	androgen	excess	 (serum	testosterone	>	2	nmol/L)	
was	observed	in	20	565	women	(25.1%);	of	those,	2481	women	(3.0%)	
had	severe	androgen	excess	(serum	testosterone	≥	3.5	nmol/L).	Serum	
SHBG	concentrations	<	20	nmol/L	were	observed	in	2517	(15.8%)	men	
and	3733	(8.9%)	women	(Supporting	Information	Tables	S1‐S4).
3.2 | Association between sex hormones and T2DM 
risk in men
Among	70	541	men	with	serum	testosterone	measurements,	3156	de‐
veloped	T2DM	during	the	follow‐up	period.	As	expected,	increasing	age,	
overweight/obesity,	smoking	and	higher	social	deprivation	conferred	an	
increased	risk	for	T2DM	(Supporting	Information	Tables	S5	and	S6).
After	adjusting	for	age,	BMI,	Townsend	index	and	smoking	sta‐
tus,	aIRR	for	T2DM	in	men	increased	with	decreasing	categories	of	
serum	testosterone	concentrations,	most	notably	a	271%	higher	risk	
of	developing	T2DM	 in	 those	with	 testosterone	 levels	<	7	nmol/L,	
compared	to	the	reference	category	of	≥20	nmol/L	(aIRR	2.71,	95%	CI	
2.34‐3.14,	P	<	0.001,	Table	2).	However,	the	risk	of	T2DM	increased	
even	within	 the	normal	male	 testosterone	range	 (15‐19.99	nmol/L,	
aIRR	1.29,	95%	CI	1.13‐1.47,	P	<	0.001;	10‐14.99	nmol/L,	aIRR	1.90,	
95%	CI	1.68‐2.15,	P	<	0.001,	Table	2	&	Figure	1A,B).
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In	the	SHBG	cohort,	among	15	907	men	studied,	there	were	708	
cases	of	 incident	T2DM	during	 the	 follow‐up	period.	After	adjust‐
ing	 for	 age,	 BMI,	 Townsend	 index	 and	 smoking	 status,	 the	 risk	 of	
T2DM	increased	in	men	with	SHBG	levels	<	40	nmol/L;	aIRR	of	in‐
cident	T2DM	increased	across	categories	of	decreasing	SHBG	con‐
centrations	as	compared	to	the	reference	category	(≥60	nmol/L)	and	 
the	 risk	 was	 more	 than	 5‐fold	 higher	 in	 the	 group	 with	 SHBG	
<	20	nmol/L	(aIRR	5.74,	95%	CI	3.72‐8.87,	Table	2	&	Figure	1C,D).
3.3 | Association between sex hormones and T2D 
risk in women
Among	 81	889	 women	 with	 serum	 testosterone	 measurements,	
1282	 developed	 T2DM	 during	 the	 follow‐up	 period.	 After	 ad‐
justing	 for	 age,	 BMI,	 Townsend	 index	 and	 smoking	 status,	 T2DM	
aIRR	 tended	 to	 be	 higher	with	 increasing	 serum	 testosterone	 lev‐
els.	 The	 risk	 increased	 significantly	 for	 serum	 testosterone	 lev‐
els	>	1.5	nmol/L,	as	compared	to	reference	category	(<1	nmol/L),	and	
continued	 to	 increase	across	each	category	of	 serum	 testosterone	
concentrations	thereafter,	with	a	twofold	 increase	 in	risk	observed	
in	 women	 with	 serum	 testosterone	≥	3.5	nmol/L	 (aIRR	 1.98,	 95%	
CI	1.55‐2.52,	P	<	0.001,	Table	2	&	Figure	2A,B).	Further	adjustment	
for	a	diagnosis	of	PCOS	or	clinical	features	of	suspected	PCOS	(hir‐
sutism	or	anovulation)	did	not	substantially	change	results	 (aIRR	 in	
subgroup	 of	 women	 with	 testosterone	 levels	>	3.5	nmol/L	=	1.89,	
95%	CI	1.48‐2.42,	P	<	0.001	and	1.76,	95%	CI	1.38‐2.25,	P	<	0.001	
respectively,	Supporting	Information	Table	S7).
In	the	SHBG	cohort,	among	42	034	women	studied,	there	were	
597	cases	of	incident	T2DM	during	the	follow‐up	period.	The	risk	of	
incident	T2DM	 increased	with	each	category	of	decreasing	SHBG	
concentration.	Women	with	serum	SHBG	concentrations	<20	nmo‐
l/L	 had	 a	9‐fold	higher	 risk	 of	 developing	T2DM	compared	 to	 the	
reference	 category	 of	 ≥60	nmol/L	 (aIRR	 9.23,	 95%	 CI	 6.61‐12.88,	
P	<	0.001),	 after	 adjustment	 for	 age,	 BMI,	 Townsend	 index	 and	
smoking	status	(Table	2	&	Figure	2C,D).	Additional	adjustment	for	a	
diagnosis	of	PCOS	and	clinical	features	of	suspected	PCOS	did	not	
alter	the	risk	of	T2DM	(aIRR	9.13,	95%	CI	6.53‐12.75,	P	<	0.001	and	
aIRR	8.88,	95%	CI	6.36‐12.42,	P	<	0.001,	respectively,	Table	S8).
3.4 | Analysis of sex hormones as a 
continuous variable
In	men,	 for	every	nmol/L	decrease	 in	 testosterone,	 the	 risk	of	
T2DM	increased	by	5%	(aIRR	1.05,	95%	CI	1.04‐1.06,	P	<	0.001).	
TA B L E  1  Baseline	characteristics	of	the	testosterone	and	SHBG	cohorts	stratified	by	sex
Characteristics
Men Women
Serum testosterone Serum SHBG Serum testosterone Serum SHBG
Population,	n	(%) 70	541	(46.28) 15	907	(27.45) 81	889	(53.72) 42	034	(72.55)
Age	(years),	mean	(SD) 51.6	(14.8) 51.7	(16.0) 33.2	(10.9) 32.1	(10.6)
Townsend	index	n	(%)
1	(least	deprived) 20	017	(28.38) 3997	(25.13) 18	470	(22.55) 8753	(20.82)
2 15	481	(21.95) 3427	(21.54) 15	688	(19.16) 7688	(18.29)
3 13	687	(19.40) 3033	(19.07) 17	043	(20.81) 8681	(20.65)
4 10	997	(15.59) 2565	(16.12) 15	295	(18.68) 8155	(19.40)
5	(most	deprived) 7374	(10.45) 2186	(13.74) 10	269	(12.54) 5955	(14.17)
Missing	or	implausible	data 2985	(4.23) 699	(4.39) 5124	(6.26) 2802	(6.67)
BMI	(kg/m2)	categorized,	n	(%)
<25 19	195	(27.21) 3995	(25.11) 32	519	(39.71) 15	975	(38.00)
25‐30 25	962	(36.80) 5817	(36.57) 16	849	(20.58) 8445	(20.09)
>30 14	502	(20.56) 3978	(25.01) 19	791	(24.17) 10	825	(25.75)
Missing	or	implausible	data 10	882	(15.43) 2117	(13.31) 12	730	(15.55) 6789	(16.15)
Smoking	status,	n	(%)
Non‐smokers 53	311	(75.57) 12	264	(77.10) 61	288	(74.84) 31	557	(75.07)
Smokers 15	325	(21.72) 3377	(21.23) 18	020	(22.01) 9312	(22.15)
Missing	or	implausible	data 1905	(2.70) 266	(1.67) 2581	(3.15) 1165	(2.77)
Confounding	conditions
PCOS 5136	(6.27) 3303	(7.86)
Anovulation 21	148	(25.83) 11	288	(26.85)
Hirsutism 9133	(11.15) 5064	(12.05)
Follow‐up	in	years,	median	(IQR) 3.3	(1.5‐6.1) 2.8	(1.3	‐	4.9) 3.2	(1.3‐6.2) 2.8	(1.2‐5.4)
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In	women,	 for	 every	 nmol/L	 increase	 in	 testosterone,	 the	 risk	
of	 T2DM	 increased	 by	 10%	 (aIRR	 1.10,	 95%	 CI	 1.06‐1.14,	
P	<	0.001).	 In	the	analysis	of	SHBG,	for	every	nmol/L	decrease	
in	 SHBG	 the	 risk	 of	 T2DM	 increased	 by	 3%	 in	 both	 men	 and	
women	(aIRR	1.03,	95%	CI	1.03‐1.04,	P	<	0.001,	in	both	sexes).
3.5 | Free androgen index and risk of T2DM
Only	 40%	 women	 (n	=	34	578)	 and	 16%	 of	 men	 (n	=	12	178)	 had	
undergone	 a	 simultaneous	 measurement	 of	 serum	 SHBG	 and	
testosterone.	Using	these	to	calculate	the	free	androgen	index	(FAI),	
we	 found	 that	FAI	was	positively	associated	with	 risk	of	T2DM	 in	
women	 (aIRR	 1.03,	 95%	 CI	 1.02‐1.04,	 P	<	0.001),	 but	 not	 in	 men	
(aIRR	1.00,	95%	CI	0.997‐1.004,	P	=	0.789).
3.6 | Subgroup analyses
Subgroup	 analysis	 stratified	 by	 age	 (<50	 and	 ≥50	years)	 did	 not	
alter	 the	observed	associations.	 In	both	age	groups,	a	gradient	 in‐
crease	in	risk	of	T2DM	was	observed	with	increasing	testosterone	
TA B L E  2  Risk	of	incident	T2DM	according	to	the	category	of	serum	testosterone	and	SHBG	at	baseline
IRR (95% CI); P‐value
Adjusteda Adjustedb Adjustedc Adjustedd
Men
Serum	testosterone	concentration	categories	(nmol/L)
<7 3.82	(3.31‐4.41);	P	<	0.001 2.60	(2.25‐3.00);	P	<	0.001 2.71	(2.34‐3.14);	P	<	0.001
7‐9.99 3.70	(3.24‐4.22);	P	<	0.001 2.46	(2.15‐2.81);	P	<	0.001 2.57	(2.24‐2.94);	P	<	0.001
10‐14.99 2.40	(2.13‐2.71);	P	<	0.001 1.83	(1.62‐2.06);	P	<	0.001 1.90	(1.68‐2.15);	P	<	0.001
15‐19.99 1.45	(1.27‐1.66);	P	<	0.001 1.25	(1.09‐1.43);	P	=	0.001 1.29	(1.13‐1.47);	P	<	0.001
≥20 Ref Ref Ref
Serum	SHBG	concentration	categories	(nmol/L)
<20 8.23	(5.37‐12.63);	P	<	0.001 5.00	(3.24‐7.71);	P	<	0.001 5.74	(3.72‐8.87);	P	<	0.001
20‐29.99 4.30	(2.83‐6.53);	P	<	0.001 2.92	(1.91‐4.44);	P	<	0.001 3.20	(2.09‐4.87);	P	<	0.001
30‐39.99 3.33	(2.19‐5.08);	P	<	0.001 2.45	(1.60‐3.74);	P	<	0.001 2.61	(1.71‐3.99);	P	<	0.001
40‐49.99 1.56	(0.98‐2.50);	P	=	0.063 1.28	(0.80‐2.06);	P	=	0.298 1.36	(0.85‐2.17);	P	=	0.207
50‐59.99 1.07	(0.61‐1.87);	P	=	0.825 0.88	(0.50‐1.54);	P	=	0.654 0.91	(0.52‐1.60);	P	=	0.748
≥60 Ref Ref Ref
Women
Serum	testosterone	concentration	categories	(nmol/L)
<1 Ref Ref Ref Ref
1.0‐1.49 1.21	(1.02‐1.43);	P	=	0.030 1.12	(0.95‐1.33);	P	=	0.184 1.12	(0.94‐1.32);	P	=	0.204 1.11	(0.94‐1.32);	P	=	0.213
1.5‐1.99 1.45	(1.23‐1.70);	P	<	0.001 1.26	(1.07‐1.48);	P	=	0.005 1.23	(1.05‐1.45);	P	=	0.011 1.23	(1.04‐1.44);	P	=	0.013
2.0‐2.49 1.70	(1.42‐2.04);	P	<	0.001 1.34	(1.12‐1.61);	P	=	0.002 1.30	(1.08‐1.56);	P	=	0.005 1.28	(1.07‐1.54);	P	=	0.008
2.5‐2.99 2.07	(1.67‐2.58);	P	<	0.001 1.59	(1.27‐1.97);	P	<	0.001 1.53	(1.23‐1.90);	P	<	0.001 1.50	(1.20‐1.87);	P	<	0.001
3.0‐3.49 2.51	(1.90‐3.32);	P	<	0.001 1.74	(1.31‐2.30);	P	<	0.001 1.68	(1.27‐2.23);	P	<	0.001 1.62	(1.22‐2.15);	P	=	0.001
≥3.5 3.00	(2.36‐3.82);	P	<	0.001 2.09	(1.64‐2.67);	P	<	0.001 1.98	(1.55‐2.52);	P	<	0.001 1.89	(1.48‐2.42);	P	<	0.001
Serum	SHBG	concentration	categories	(nmol/L)
<20 19.76	(14.36‐27.21);	P	<	0.001 8.96	(6.42‐12.50);	P	<	0.001 9.23	(6.61‐12.88);	P	<	0.001 9.13	(6.53‐12.75);	P	<	0.001
20‐29.99 8.66	(6.29‐11.93);	P	<	0.001 4.45	(3.20‐6.19);	P	<	0.001 4.48	(3.22‐6.24);	P	<	0.001 4.44	(3.19‐6.18);	P	<	0.001
30‐39.99 4.66	(3.31‐6.57);	P	<	0.001 2.69	(1.90‐3.82);	P	<	0.001 2.70	(1.91‐3.84);	P	<	0.001 2.69	(1.90‐3.82);	P	<	0.001
40‐49.99 2.99	(2.04‐4.38);	P	<	0.001 2.05	(1.40‐3.02);	P	<	0.001 2.08	(1.41‐3.05);	P	<	0.001 2.07	(1.41‐3.05);	P	<	0.001
50‐59.99 1.64	(1.02‐2.64);	P	=	0.043 1.29	(0.80‐2.08);	P	=	0.295 1.29	(0.80‐2.07);	P	=	0.304 1.29	(0.80‐2.08);	P	=	0.301
≥60 Ref Ref Ref Ref
IRR,	incidence	rate	ratio;	SHBG,	sex	hormone‐binding	globulin;	T2DM,	type	2	diabetes	mellitus
aAdjusted	for	age.	
bAdjusted	for	age,	BMI.	
cAdjusted	for	age,	BMI,	Townsend	index,	smoking	status.	
dAdjusted	for	age,	BMI,	Townsend	index,	smoking	status,	PCOS.	
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concentrations	 in	women	 and	 decreasing	 testosterone	 concentra‐
tions	in	men	(Figure	S1;	Tables	S9‐S12).	Increased	aIRRs	for	T2DM	
were	noted	with	lower	concentrations	of	SHBG	in	both	age	groups	
in	men	and	women	(Figure	S2;	Tables	S13‐S16).
4  | DISCUSSION
In	this	large	retrospective	cohort	study,	we	have	demonstrated	that	
androgens	confer	an	independent	sex‐specific	effect	on	the	risk	of	
incident	T2DM.	To	our	knowledge,	this	is	the	largest	study,	and	the	
first	longitudinal	analysis,	to	address	the	impact	of	serum	testoster‐
one	on	risk	of	development	of	T2DM	in	both	men	and	women.	In	the	
female	cohort,	aIRRs	for	T2DM	increased	significantly	once	serum	
testosterone	concentrations	increased	above	1.5	nmo/L;	even	those	
with	 circulating	 testosterone	 levels	 between	1.5	 and	1.99	nmol/L,	
conventionally	considered	within	the	normal	physiological	range	for	
women,	already	had	a	23%	increased	risk	of	T2DM	compared	to	the	
reference	group.	Perhaps	even	more	surprisingly,	once	male	serum	
testosterone	concentrations	dropped	below	20	nmol/L,	 the	risk	of	
T2DM	began	 to	 increase;	men	with	 circulating	 concentrations	be‐
tween	15	and	19.99	nmol/L,	that	is	within	the	normal	physiological	
male	range,	had	a	28%	increased	risk	of	T2DM	over	the	study	pe‐
riod.	Reduced	SHBG	concentrations	 in	both	sexes,	but	particularly	
in	women,	also	potently	increased	the	risk	of	T2DM.	This	finding	is	
in	agreement	with	observations	from	some	previous	studies,	which	
demonstrated	a	stronger	inverse	association	between	SHBG	levels	
and	risk	of	T2DM	in	women	compared	to	men.9,21	This	inverse	rela‐
tionship	with	T2DM	appears	to	be	particularly	strong	in	postmeno‐
pausal	women.22	A	2011	meta‐analysis,	however,	found	that	higher	
SHBG	 levels	were	equally	associated	with	a	 reduced	risk	of	meta‐
bolic	syndrome	in	both	sexes.23
A	systematic	review	and	meta‐analysis,	which	included	a	total	of	
3825	men	and	4795	women	in	36	cross‐sectional	studies,	as	well	as	
368	cases	from	7	prospective	study	populations,	previously	demon‐
strated	 that	 increased	 serum	 testosterone	 was	 associated	 with	 a	
60%	higher	 risk	of	T2DM	 in	women;	higher	 testosterone	 levels	 in	
men	reduced	the	risk	of	T2DM	by	42%.9	Goodman‐Gruen	et al24	also	
observed	sex	differences	in	the	association	between	serum	andro‐
gens	and	glucose	tolerance	status	in	an	older	community	cohort	of	
775	men	and	633	women	above	the	age	of	55.	Men	with	impaired	
fasting	glucose,	 impaired	glucose	 tolerance	and	T2DM	had	signifi‐
cantly	lower	levels	of	serum	testosterone,	while	women	with	T2DM	
had	significantly	higher	levels	of	bioavailable	testosterone,	indepen‐
dent	of	total	body	fat,	fat	distribution,	physical	activity	and	smoking.	
However,	our	study	is	the	only	longitudinal	retrospective	analysis	to	
comprehensively	evaluate	these	associations.
A	 number	 of	 key	 insights	 into	 the	 role	 of	 androgen	 excess	 in	
the	development	of	metabolic	dysfunction	are	provided	by	stud‐
ies	 in	women	with	polycystic	ovary	 syndrome	 (PCOS),	 a	disorder	
F I G U R E  1  Risk	of	incident	type	2	diabetes	(T2DM)	according	to	serum	testosterone	and	sex	hormone‐binding	globulin	(SHBG)	
concentration	categories	in	men.	A,	Adjusted	Incidence	Rate	Ratios	(aIRRs)	for	diabetes	in	70	541	men	with	serum	testosterone	
measurements.	B,	Distribution	of	70	541	men	across	each	quintile	of	serum	testosterone	concentration.	C,	aIRRs	for	serum	SHBG	
concentrations	for	incident	diabetes	in	15	907	men.	D,	Distribution	of	15	907	men	across	each	category	of	serum	SHBG	concentration
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affecting	up	to	10%	of	the	female	population	and	primarily	defined	
by	the	presence	of	hyperandrogenism	and	ovulatory	dysfunction.25 
We	have	recently	demonstrated	that	lean	women	with	PCOS	have	
an	almost	twofold	increased	risk	of	NAFLD,	a	hepatic	manifestation	
of	metabolic	dysfunction,	and	that	androgen	excess	is	an	indepen‐
dent	mediator	of	this	increased	risk.3	Androgen‐mediated	adipose	
tissue	lipotoxicity	may	contribute	to	this	increase	in	NAFLD	risk.4,26 
PCOS	women	are	at	significantly	increased	risk	of	impaired	glucose	
tolerance	and	T2DM	at	a	young	age,	irrespective	of	body	weight.27 
A	 recent	 large	 Danish	 population	 register	 study	 concluded	 that	
the	risk	of	T2DM	was	fourfold	higher	for	women	with	PCOS,	and	
diagnosed	4	years	earlier,	compared	to	women	in	the	background	
population.28
Male	androgen	deficiency	occurs	as	a	consequence	of	primary	
testicular	 pathology,	 hypothalamic‐pituitary	 disorders,	 obesity	 or	
as	 part	 of	 the	 ageing	 process	 in	 older	men.29,30	 Additionally,	 iat‐
rogenic	 hypogonadism	 due	 to	 androgen	 deprivation	 therapy	 is	
observed	 in	 men	 with	 prostate	 cancer.31	Whilst	 the	 relationship	
between	 obesity	 and	 hypogonadism	 in	men	 is	 complex	 and	 bidi‐
rectional,32	data	from	male	cohorts	treated	with	short‐term	andro‐
gen	deprivation	therapy	show	that	hypogonadism	directly	induces	
metabolically	 deleterious	 changes	 in	 body	 composition,	 with	 in‐
creases	 in	 weight	 and	 in	 percentage	 fat	 body	 mass.33	 However,	
studies	of	androgen	deprivation	therapy,	which	result	in	significant	
hypogonadism,	are	not	an	ideal	model	to	compare	to	the	relatively	
modest	reductions	in	testosterone	observed	in	community‐dwell‐
ing	older	men.	The	results	of	our	study	are	particularly	surprising,	
given	that	an	 increased	risk	of	T2DM	was	apparent	at	circulating	
testosterone	 concentrations	 considered	 physiologically	 normal,	
but	below	the	reference	group	of	20	nmol/L,	independent	of	age,	
obesity	 and	 other	 potential	 confounding	 factors.	 However,	 our	
results	do	not	 imply	endorsement	of	 testosterone	pharmacother‐
apy	 to	 restore	 circulating	 testosterone	 levels	 above	20	nmol/L	 in	
otherwise	healthy	men.	Studies	investigating	a	potential	beneficial	
impact	 of	 androgen	 therapy	on	metabolic	 outcomes	 in	men	with	
testosterone	concentrations	 in	the	 low	or	 low‐normal	range	have	
shown	at	best	conflicting	 results.	A	 recent	double‐blind	placebo‐
controlled	trial	of	testosterone	treatment	in	788	older	men	showed	
no	impact	on	serum	glucose	or	HbA1C34;	another	study	showed	no	
change	 in	 insulin	 sensitivity	 after	36	months	of	 treatment	 in	308	
community‐dwelling	men.35	 The	 2018	 Endocrine	 Society	 Clinical	
Practice	Guideline	on	 testosterone	 therapy	 in	men	with	hypogo‐
nadism	no	 longer	 recommend	screening	men	with	T2DM	for	 low	
serum	testosterone,	and	advise	against	using	testosterone	therapy	
to	improve	glycaemic	control.36
Low	 circulating	 SHBG	 has	 been	 consistently	 identified	 as	 a	
surrogate	marker	 for	T2DM	in	both	sexes	 in	a	number	of	smaller	
studies	 and	 meta‐analyses,9,37,38	 and	 our	 study	 supports	 these	
F I G U R E  2  Risk	of	incident	type	2	diabetes	(T2DM)	according	to	serum	testosterone	and	sex	hormone‐binding	globulin	(SHBG)	
concentrations	in	women.	A,	Adjusted	Incidence	Rate	Ratios	(aIRRs)	for	incident	diabetes	in	81	889	women	with	serum	testosterone	
measurements.	B,	Distribution	of	81	889	women	across	each	category	of	serum	testosterone	concentration.	C,	aIRRs	for	serum	SHBG	
concentrations	for	incident	diabetes	in	42	034	women	with	serum	SHBG	measurements.	D,	Distribution	of	42	034	women	across	each	
category	of	serum	SHBG	concentration
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observations.	 In	 a	 meta‐analysis	 of	 13	 population‐based	 studies	
with	1912	incident	cases	of	T2DM,	low	SHBG	was	associated	with	
increased	risk	of	T2DM	in	women,	irrespective	of	menopausal	sta‐
tus.37	SHBG	levels	are	typically	higher	in	women,	and	our	data	con‐
firm	that	reduced	circulating	concentrations	are	associated	with	a	
higher	risk	of	T2DM	than	that	observed	in	men.	SHBG	is	a	critical	
mediator	 of	 the	 association	 between	 sex	 steroids	 and	metabolic	
dysfunction.	The	majority	of	 circulating	 testosterone	 is	bound	 to	
SHBG,	 such	 that	 only	 the	 unbound	 or	 “free”	 fraction	 is	 capable	
of	 exerting	 effects	 in	 target	 tissues.39	 Therefore,	 reduced	 SHBG	
levels	 in	 women	 are	 a	 surrogate	 marker	 of	 increased	 circulating	
active	 androgens.	 Insulin	 is	 a	 potent	 regulator	 of	 hepatic	 SHBG	
output,	which	 is	 suppressed	 in	 the	 context	of	 hyperinsulinaemia,	
leading	to	reduced	SHBG,	and	therefore	increased	free	androgens,	
in	insulin‐resistant	states	such	as	PCOS	in	women.40	It	is	unlikely,	
however,	that	SHBG	independently	plays	a	causal	role	in	the	patho‐
physiology	 of	metabolic	 diseases	 such	 as	 T2DM.	 Low	SHBG	and	
testosterone	levels	in	men	are	likely	to	be	mediated	by	obesity	in	
a	population	already	at	increased	risk.41	We	found	that	FAI	in	men	
did	not	have	a	negative	linear	association	with	T2DM	risk,	indicat‐
ing	that	 low	SHBG	rather	than	testosterone	 is	the	predominantly	
associated	with	metabolic	risk	in	men.	This	supports	the	observa‐
tions	 of	Bhasin,42	 but	 conflicts	with	 those	of	Haring	et al,43 who 
found	that	declining	testosterone	rather	than	SHBG	levels	were	the	
main	driver	of	metabolic	syndrome	in	a	large	German	cohort.	It	is	
important	to	note	that	FAI	must	be	interpreted	with	caution	in	both	
men	and	women,	and	is	particularly	inaccurate	in	women	when	the	
SHBG	concentration	falls	below	30	nmol/L.44
This	 study	 has	 a	 number	 of	 important	 limitations,	 not	 least	 its	
retrospective	nature.	Detailed	clinical	phenotyping	in	studies	of	this	
type	is	not	possible.	There	are	also	no	detailed	data	available	on	lab‐
oratory	assays	used	 to	measure	serum	testosterone.	This	 is	not	of	
particular	concern	in	men,	as	physiologically	higher	testosterone	con‐
centrations	do	not	represent	a	challenge	for	quantification	by	either	
radioimmunoassay	(RIA)	or	tandem	mass	spectrometry	techniques.	
In	women,	however,	where	low	circulating	concentrations	pose	sig‐
nificant	analytical	 and	quantification	difficulties	 for	 standard	RIAs,	
the	 consensus	 is	 that	 today	 measurements	 should	 be	 performed	
by	 liquid	 chromatography‐tandem	 mass	 spectrometry	 to	 improve	
quantification	and	avoid	cross‐reactivity.45	Furthermore,	we	have	no	
information	on	the	time	of	day	blood	sampling	for	serum	testoster‐
one	took	place;	in	men,	Endocrine	Society	guidelines	emphasize	that	
morning	samples	are	crucial	to	accurately	diagnose	hypogonadism.46 
Lastly,	we	must	assume	that	testosterone	data	were	obtained	from	
men	and	women	with	a	clinical	 indication	for	serum	measurement;	
this	 introduces	a	potential	bias	by	 indication.	However,	we	believe	
that	these	limitations	are	ameliorated	by	the	large	patient	numbers	
and	the	clear	and	potent	gradient	towards	sex‐specific	T2DM	risk	in	
the	study	population.
In	conclusion,	 in	the	 largest	retrospective	 longitudinal	study	of	
its	 kind,	 we	 have	 demonstrated	 evidence	 of	 a	 sexually	 dimorphic	
role	 for	androgens	 in	mediating	the	risk	of	T2DM.	Reduced	SHBG	
levels	in	both	sexes,	but	particularly	in	women,	significantly	increase	
the	risk	of	T2DM.	These	data	further	define	androgens	as	a	novel	
metabolic	risk	factor	in	men	and	women,	but	potential	mechanisms	
underpinning	these	observations	remain	to	be	clarified.	We	suggest	
that	 women	 with	 androgen	 excess	 and	 men	 with	 androgen	 defi‐
ciency	should	be	systematically	screened	for	T2DM.	Future	studies	
will	 be	 required	 to	 show	 if	 reducing	androgens	 in	women,	 and	 in‐
creasing	androgens	in	men,	will	improve	overall	metabolic	health	and	
risk	of	progression	to	overt	T2DM.
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